When aciclovir is used for several days, yes it would work by inhibiting viral replication. I'm saying you can't apply the same logic to the first hour.
You're right that the drug concentration peaks in the blood in one hour. What you're missing from the pharmacodynamic perspective is that this does not mean that viral load starts declining rapidly within one hour. A full cycle of HSV replication takes closer to 12 hours to complete, similar to other viruses in that family. The drug does not kill or clear the virus, just prevents further replication. So within the first hour, viral load will only be reduced by a small fraction at most (see
this paper, figure 7). And that's assuming that the drug immediately gets to all the infected cells and binds to the right proteins to cease all viral replication immediately--which, if you know anything about pharmacodynamics, is a fantasy.
The vast majority of fully formed viral particles and immunogenic viral fragments are going to be sticking around and still triggering an infection response until they are all cleared out by the immune system (which takes hours/days). Basically all the symptoms that you feel from an infection, whether that is local inflammation of a cold sore or malaise/brain fog, are caused by immune signaling responding to that virus,
not the virus itself. So
even if there was a meaningful reduction in viral replication in the first hour--let's be generous and say something like 5%--the immune system would still be reacting to the leftover fragments and still causing symptoms as if there was no change in viral replication.
However, there is a possible explanation for why aciclovir could possibly cause a symptom reduction within an hour besides placebo effect--in addition to inhibiting viral DNA polymerase, it also directly targets proteins in immune cells. Very simple experiments show that this is likely true (
example). It's also possible it targets something directly in the nervous system that would alter the feelings of pain or brain fog or malaise. [Edit: what would need to be established in a clinical trial is whether this actually happens and contributes to symptom relief more than random fluctuation.]
It seems like this is a theory you find really personally important, so I don't think further discussion will get anywhere. Though if you think people are disagreeing because they simply don't understand pharmacological or viral dynamics, I hope this might prompt you to reassess that assumption. If infectious disease experts are telling you differently, I think that is an indication that they
don't understand those dynamics.